Oncology / Cancer | Application Support Knowledgebase | Lab Products & Services | 爱游戏平台注册登录

Oncology and preclinical imaging

Overview
Products for preclinical imaging and oncology
Application notes and posters
Citations

Overview

The development of novel and safer cancer therapeutics that target specific molecular targets and broader disease-related processes remains a need. In vivo preclinical studies can help dissect complex biological processes related to cancer (such as angiogenesis and tumor metastasis), validate potential molecular targets, and assess therapeutic response in a whole animal model. Non-invasive preclinical studies enable real-time, quantitative measurements of therapeutic outcomes while reducing the number of animals used in research. 爱游戏平台注册登录 offers targeted, activatable, and vascular fluorescent agents, as well as bioluminescent oncology cell lines, for preclinical imaging of cancer.

Products for oncology preclinical studies

Angiogenesis

Agent	Agent Type	Agent Mechanism	Available Wavelengths and optimal in vivo imaging time (post-injection)	Route of metabolism/ background tissue(s)	Validated imaging methods*
IntegriSense™	Targeted; fluorescent	Binds to α5β3 integrin. This integrin is upregulated in activated endothelial cells during angiogenesis.	645 nm (6-24 h), 680 nm (3-48 h), 750 nm (24 h)	Bladder/kidneys (645 nm), kidneys/intestine (680 nm), kidneys (750 nm)	In vivo/ex vivo; in vitro microscopy
HypoxiSense™	Targeted; fluorescent	Binds to carbonic anhydrase IX which is expressed in hypoxic tissue, a result of abherrant vasculature.	680 nm (24 h)	Kidneys	In vivo/ex vivo; flow cytometry; in vitro microscopy
TLectinSense™	Targeted; fluorescent	Binds to tomato lectin, a well-known tool for studying for studying tumor angiogenesis and measuring microvessel density. This agent provides direct labeling of the vascular endothelial cells.	680 nm (6 h)	Overall vascular background	In vivo/ex vivo; flow cytometry; in vitro microscopy
AngioSense^®	Vascular; fluorescent	A high molecular weight agent with a moderate blood half-life (7 hours), used to assess vascular leak, with ideal imaging times of 24 hours post-injection.	680 nm (24 hours) 750 nm (24 hours)	Low liver lung	In vivo/ex vivo; flow cytometry; in vitro microscopy
AngioSPARK^®	Vascular; fluorescent	Pegylated fluorescent nanoparticles that remain localized in the vasculature for extended periods of time and enable imaging of blood vessels and angiogenesis	680 nm (0 - 4 hours)	Long term tissue accumulation	In vivo
Superhance^®	Vascular; fluorescent	Blood pooling agent	680 nm (0.5 - 24 h)	Bladder	In vivo

Apoptosis

Agent	Agent Type	Agent Mechanism	Available Wavelengths and optimal in vivo imaging time (post-injection)	Route of metabolism/ background tissue(s)	Validated imaging methods*
Annexin-Vivo™	Targeted; fluorescent	Labels cells that are undergoing the early stages of apoptosis	750 nm (2 h)	Kidneys (high), liver	In vivo/Ex vivo, Flow cytometry, In vitro microscopy

Tumor growth

Agent	Agent Type	Agent Mechanism	Available Wavelengths and optimal in vivo imaging time (post-injection)	Route of metabolism/ background tissue(s)	Validated imaging methods*
Cat B FAST™	Activatable; fluorescent	Produces fluorescent signal after cleavage by Cathepsin B produced by tumor cells	680: 6-24 hours 750: 6-24 hours	Salivary glands, liver, kidneys	In vivo, flow cyometry, in vitro cell microscopy, frozen tissue labeling
MMPSense^®	Activatable; fluorescent	Matrix metalloproteinase (MMP)-activatable agent that produces fluorescent signal after cleavage by disease related MMP’s. MMP activity is involved in many disease-related processes including cancer progression, invasion and metastasis.	645 FAST: 24 h (6-24 h) 680: 24 h (24-36 h) 750 FAST: 12 h (12-24 h)	Liver, kidneys (645 FAST, 750 FAST) Liver only (680)	In vivo
ProSense^®	Activatable; fluorescent	Activated by key disease associated proteases such as Cathepsin B, L, S and Plasmin. Can be used as a marker for disease progression in animal tumor models	680: 24 h (24-48 h) 750: 24 h 750 FAST*: 6-24 h	Liver (680) Low liver (750) Low liver, bladder (750 FAST)	In vivo, flow cytometry, in vitro cell microscopy
COX-2 probe	Targeted; fluorescent	Efficiently target cyclooxygenase-2 (COX-2), which is normally absent from cells, but is found at high levels in inflammatory lesions and in many premalignant and malignant tumors	600: 3 h	Kidney and liver	In vivo, in vitro cell microscopy
FolateRSense™	Targeted; fluorescent	Highly specific and sensitive in its detection of Folate Receptor alpha (FRA); can be used to closely monitor and quantitate tumor growth and metabolism	680: 6 h (6-24 h)	kidneys	In vivo, flow cytometry, in vitro cell microscopy, frozen tissue labeling
IntegriSense™	Targeted; fluorescent	Small molecule αvß3 integrin antagonist that contains a NIR fluorophore reporter. This targeted agent detects increased integrin expression associated with neovasculature, tumors, and some inflammatory cells associated with atherosclerosis.	645 nm (48 h) 680 nm (24 h) 750 nm (24 h)	Bladder/kidneys (645 nm) Kidneys/intestine (680 nm) Kidneys (750 nm)	In vivo/Ex vivo, Flow cytometry, In vitro microscopy
Transferrin-Vivo™	Targeted; fluorescent	Recombinant transferrin conjugated to VivoTag dye; designed to bind to transferrin receptors expressed in cancer cells.	770: 24 h	Liver, kidney	In vivo, ex vivo, flow cytometry, in vitro cell microscopy, frozen tissue labeling
FolateRSense™	Targeted; fluorescent	Highly specific and sensitive in its detection of Folate Receptor alpha (FRA); can be used to closely monitor and quantitate tumor growth and metabolism	680: 6 h (6-24 h)	kidneys	In vivo, flow cytometry, in vitro cell microscopy, frozen tissue labeling
OsteoSense^®	Targeted; fluorescent	Bisphosphonate imaging agent that enables imaging of bone growth and resorption; can be used to measure bone cancer metastasis.	680: 3-24 h 750: 3-24 h 800: 3-24 h	Bladder	In vivo
TLectinSense™	Targeted; fluorescent	Targets the vasculature and enables imaging of tumor neo-vasculature, characterized by the development of abnormal, leaky and tortuous blood vessels.	680 nm (6 h)	Overall vascular background	In vivo/ex vivo; flow cytometry; in vitro microscopy
AngioSense^®	Vascular; fluorescent	A high molecular weight agent with a moderate blood half-life (7 hours), used to assess vascular leak, with ideal imaging times of 24 hours post-injection.	680 nm (24 hours) 750 nm (24 hours)	Low liver lung	In vivo/ex vivo; flow cytometry; in vitro microscopy
AngioSPARK^®	Vascular; fluorescent	Pegylated fluorescent nanoparticles that remain localized in the vasculature for extended periods of time and enable imaging of blood vessels and angiogenesis	680 nm (0 - 4 hours)	Long term tissue accumulation	In vivo
Superhance^®	Vascular; fluorescent	Blood pooling agent	680 nm (0.5 - 24 hours)	Bladder	In vivo
Bioware Ultra Cell Lines	Bioluminescence or dual bioluminescence/ fluorescence	Bioluminescent oncology cell lines (also known as Bioware cell lines) are stably transfected with a luciferase (luc or luc2) reporter gene that allows you to visualize the growth of the cells in vivo. The cell lines are injected into an appropriate mouse model to monitor early tumor development, monitor tumor growth and metastases, quantify tumor burden in a whole animal model, and follow therapeutic responses non-invasively.	n/a		In vivo, ex vivo (dual)

Metastasis

Agent	Agent Type	Agent Mechanism	Available Wavelengths and optimal in vivo imaging time (post-injection)	Route of metabolism/ background tissue(s)	Validated imaging methods*
2-DG 750 Probe	Targeted; fluorescent	In vivo targeting of tumors that typically exhibit elevated glucose uptake rate in comparison to surrounding tissues	820: 3 h	Bladder	In vivo
MMPSense	Activatable; fluorescent	Matrix metalloproteinase (MMP)-activatable agent that produces fluorescent signal after cleavage by disease related MMP’s. MMP activity is involved in many disease-related processes including cancer progression, invasion and metastasis.	645 FAST: 24 h (6-24 h) 680: 24 h (24-36 h) 750 FAST: 12 h (12-24 h)	Liver, kidneys (645 FAST, 750 FAST) Liver only (680)	In vivo
OsteoSense	Targeted; fluorescent	Bisphosphonate imaging agent that enables imaging of bone growth and resorption; can be used to measure bone cancer metastasis.	680: 3-24 h 750: 3-24 h 800: 3-24 h	Bladder	In vivo
Bioluminescent oncology cell lines	Bioluminescence or dual bioluminescence/ fluorescence	Bioluminescent oncology cell lines (also known as Bioware cell lines) are stably transfected with a luciferase (luc or luc2) reporter gene that allows you to visualize the growth of the cells in vivo. The cell lines are injected into an appropriate mouse model to monitor early tumor development, monitor tumor growth and metastases, quantify tumor burden in a whole animal model, and follow therapeutic responses non-invasively.	n/a		In vivo, ex vivo (dual)

Hypoxia

Agent	Agent Type	Agent Mechanism	Available Wavelengths and optimal in vivo imaging time (post-injection)	Route of metabolism/ background tissue(s)	Validated imaging methods*
HypoxiSense	Targeted; fluorescent	Detects the tumor cell surface expression of carbonic anhydrase 9 (CA IX) protein, which increases in hypoxic regions within many tumors, especially in cervical, colorectal, non-small cell lung tumors	680: 24 h	Kidney	In vivo, flow cytometry, in vitro cell microscopy, frozen tissue labeling

Vasculature

Agent	Agent Type	Agent Mechanism	Available Wavelengths and optimal in vivo imaging time (post-injection)	Route of metabolism/ background tissue(s)	Validated imaging methods*
AngioSense	Vascular; fluorescent	A high molecular weight agent with a moderate blood half-life (7 hours), used to assess vascular leak, with ideal imaging times of 24 hours post-injection.	680 nm (24 hours) 750 nm (24 hours)	Low liver lung	In vivo/ex vivo; flow cytometry; in vitro microscopy
AngioSPARK	Vascular; fluorescent	Pegylated fluorescent nanoparticles that remain localized in the vasculature for extended periods of time and enable imaging of blood vessels and angiogenesis	680 nm (0 - 4 hours)	Long term tissue accumulation	In vivo
Cat B FAST	Activatable; fluorescent		680: 6-24 hours, 750: 6-24 hours	Salivary glands, liver, kidneys	In vivo, flow cyometry, in vitro cell microscopy, frozen tissue labeling
IntegriSense	Targeted; fluorescent	Small molecule αvß3 integrin antagonist that contains a NIR fluorophore reporter. This targeted agent detects increased integrin expression associated with neovasculature, tumors, and some inflammatory cells associated with atherosclerosis.	645 nm (48 h) 680 nm (24 h) 750 nm (24 h)	Bladder/kidneys (645 nm) Kidneys/intestine (680 nm) Kidneys (750 nm)	In vivo/Ex vivo, Flow cytometry, In vitro microscopy
Superhance^®	Vascular; fluorescent	Blood pooling agent	680 nm (0.5 - 24 h)	Bladder	In vivo

Choosing the right agent

When choosing an agent for acute inflammation studies, several factors should be taken into consideration:

Fluorescent vs. Chemiluminscent agents: Be sure to choose the proper agent for your instrumentation. Some imagers can measure both chemiluminescence and fluorescence, while others can only measure one or the other.
Dye excitation/emission wavelength: Some fluorescent agents are available with excitation wavelengths that range from 645 nm to 800 nm. Be sure to pick a wavelength that is appropriate for both your instrument and application. Most microscopes filters are not suitable for wavelengths above 680 nm. However deep tissue imaging typically has less background fluorescence and works better with longer wavelengths (750 nm- 800 nm).
Agent clearance time is typically faster for activatable agents (particularly the FAST™ platform) which allows for re-injection after shorter time periods.
Agent specificity: For targeted and activatable agents, it is important to remember that the protein or enzyme that the agent is targeting needs to be present and well expressed in your mouse model.
In vivo distribution: Some agents might accumulate in organs at timepoints which could interfere with your study. Be sure to check the biodistribution profile of each agent of interest.
Type of imaging required for your study: Vascular agents for example, while useful in assessing vascularity changes in the mouse, do not make good agents for in vitro cell imaging or tissue analysis. If these types of analyses are desired, targeted or activatable agents might be a better choice for you.

Application notes and posters

Poster: Non-Invasive Near-Infrared Quantitative Tomography and Agents for Quantification of Early Anti-Angiogenic Treatment Efficacy
Poster: Quantifying Syngeneic Breast Cancer Metastasis to the Lung and Response to Therapy Using Fluorescence Molecular Tomography (FMT)
Poster: Non-invasive FMT quantification of folate receptor expression in mouse tumor xenografts with a new near-infrared fluorescent folate agent
Poster: In vivo imaging of tumor hypoxia by a new near-infrared fluorescent carbonic anhydrase IX-targeted agent
Poster: In Vivo Quantification of Integrin-Targeted and Protease-Activated Imaging Agents in Response to Anti-Angiogenic Therapy using Quantitative Fluorescence Tomography

Citations

Browse or search the 爱游戏平台注册登录 Citations Library for oncology preclinical imaging citations.